Kevin Fitzgerald, PhD.

Chief Scientific Officer at Epsilogen

Speaker

Kevin began his career at Cambridge Antibody Technology (now part of AstraZeneca) when CAT was still in its start-up phase. He went on to found and manage Isogenica Ltd and has since held CEO positions with PhosImmune Inc., Activiomics Ltd and F-star GmbH. Kevin studied for his PhD in the laboratory of Sir Gregory Winter at the MRC Laboratory of Molecular Biology, Cambridge and for his MBA at Aston Business School.